Sorrento Therapeutics

 Fact Sheet

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq, the next-generation paclitaxel, will commence its registrational trial and be developed under the abbreviated 505(b)(2) regulatory pathway.

Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated Antibody Drug Conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads.

Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, therapeutic antibodies, and ADCs.

Find a broker to begin trading SRNE now

Investment HighlightsValue Proposition
Company Name Sorrento Therapeutics
Market/Symbol NASDAQ: SRNE
Recent Price
Market Cap $190.37M
Avg. Daily Vol. (3m) 1,020,205
Price/Book N/A
Price/Cash Flow N/A
As of Dec. 12, 2017
*Source: QuoteMedia

Begin trading SRNE

 Find Broker



Recent Company Videos

Sorrento Therapeutics (NASDAQCM: SRNE): RedChip Emerging Growth Showcase (January 22-23, 2014)

Jan. 27, 2014

Virtual Conference Presentation and Investor Q&A with Henry Ji, CEO of Sorrento Therapeutics (NASDAQCM: SRNE), a publicly-traded, clinical-stage ...

Investment Highlights

  • 1st generation Taxol peak product sales - $1.6 billion
  • 2nd generation Abraxane estimated peak product sales - $1.7 billion
  • Cynviloq has less side effects and provides abbreviated regulatory pathway ("bioequivalence") opportunity
  • Potential to expand Cynviloq to treat pancreatic, bladder, and ovarian cancer

  • Orphan drug status received
  • Three potential drug products from same platform

  • Very high library diversity
  • Acquisition of Concortis Biosystems provides antibody drug conjugation (ADCs) technology
  • First therapeutic antibody candidate in clinic in 1H2015

Value Proposition

The Company’s current market cap of $212.4M is substantially lower than many public companies within their competing space. We identified many comparable companies with market caps exceeding $1B. Sorrento’s near term therapy is a 3rd generation paclitaxel that is not only safer than previous generations but also provides an abbreviated regulatory pathway opportunity. A fair valuation must consider industry market cap comparisons and 1st generation paclitaxel peak sales of $1.6 billion. Sorrento’s pipeline also includes therapies to treat cancer pain as well as an extremely comprehensive antibody library.

Sorrento Therapeutics Latest News

Ask the CEO

Meet The Board of Directors

David Webb

Chairman of the Board

Ernst-Guenter Afting


Meet The Management Team

Dr. Henry Ji

Director, President and CEO

Dr. Vuong Trieu

Director and Chief Scientific Officer

George Uy

Chief Commercial Officer

Richard G. Vincent

Director, Executive Vice President and CFO

SRNE Research

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

Receive SRNE Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market